A Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR Tyrosine Kinase Inhibitor (TKI)

Diseases and Conditions Researched

Lung

What is the purpose of this trial?

- To estimate progression free survival (PFS) after locally ablative therapy and erlotinib in EGFR-mutant NSCLC patients who progressed on prior EGFR-TKI therapy

Secondary Objectives

To evaluate local control of sites previously progressive on erlotinib following SRS followed by erlotinib
To estimate overall survival (OS) after locally ablative therapy and erlotinib in EGFR-mutant NSCLC patients who progressed on prior EGFR-TKI therapy
To characterize the toxicity of SRS
To characterize the toxicity of erlotinib when preceded by SRS


Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: University of North Carolina at Chapel Hill
Dates:
Last Updated:
Study HIC#: 1403013629